Recombinant TAG-72 (Minretumomab Biosimilar) antibody

Catalog No. ABIN7072523

The Mouse Monoclonal anti-TAG-72 (Minretumomab Biosimilar) antibody has been validated for FACS, IHC, RIA and WB. It is suitable to detect TAG-72 (Minretumomab Biosimilar) in samples from Human.

Quick Overview for Recombinant TAG-72 (Minretumomab Biosimilar) antibody (ABIN7072523)

Target: TAG-72 (Minretumomab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TAG-72 (Minretumomab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Radioimmunoassay (RIA), Western Blotting (WB)

Product Details anti-TAG-72 (Minretumomab Biosimilar) Antibody

Purpose: Anti-TAG-72 [Minretumomab (CC49 )], Mouse IgG1, kappa

Specificity: This antibody is specific for the disaccharide sialyl Tn epitope of human TAG-72. TAG-72 is expressed on a wide range of human carcinomas, including colorectal cancers.

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: This antibody was raised by immunising BALB/c mice with TAG-72 purified from LS-174T human carcinoma xenograft.

Isotype: IgG1 kappa

Application Details

Application Notes: The reactivity of this antibody with colon cancer extract and purified TAG-72 has been confirmed in solid-phase radioimmunoassays, and its reactivity with formalin-fixed carcinoma tissue sections confirmed in immunoperoxidase studies (Muraro et al, 1988). In flow cytometric analysis of freshly-isolated human carcinoma cells, this antibody reacts more strongly than the anti-TAG-72 MAb B72.3 (Muraro et al, 1988). Equally, flow cytometric analyses using this antibody have revealed that TAG-72 is expressed by certain haematopoietic cell lines (Nicolet et al, 1997). In western blot analysis, this antibody reacts with TAG-72 (Muraro et al, 1988). A humanised version of this antibody has been shown to be safe and sensitive in detecting recurrent colorectal carcinomas in radioimmunoguided surgery (Agnese et al, 2004), while radioimmunotherapy with an iodine-131-conjugated antibody has been shown to have a significant therapeutic effect on metastatic colon carcinoma in Phase I trials (Divgi et al, 1995).

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for TAG-72 (Minretumomab Biosimilar)

Target: TAG-72 (Minretumomab Biosimilar)

Background: CA 72-4, Tumor-associated antigen 72, TAG72, Tumor-associated glycoprotein 72